top of page
The Professional Network for Healthcare Experts
FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults
The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria.
nuaxia
5 hours ago2 min read
Ambrose Healthcare acquires AM-Pharma in rare disease transaction worth up to €161 million
Ambrose Healthcare has acquired Netherlands-based AM-Pharma in a rare disease transaction worth up to €161 million, adding an investigational therapy for hypophosphatasia.
nuaxia
1 day ago2 min read
Merck KGaA agrees $1.3 billion acquisition of Silence Therapeutics to expand rare disease siRNA pipeline
Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion in equity, expanding its RNA interference pipeline.
nuaxia
2 days ago2 min read
bottom of page